EGFR mutations in patients with advanced NSCLC;Mutace genu EGFR u pacientů s pokročilým NSCLC

Klinicka Onkologie

Volumn 25, Issue 4, 2012, Pages 267-273

  Fiala, Ondřej ^a   Pesek M ^a   Finek J ^a   Bruha F ^a   Bortlicek Z ^b   Krejci J ^c   Benesova L ^d   Minarik M ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^d Centrum Aplikovane Genomiky Solidnich Nadoru CEGES Genomac Vyzkumny Ustav Praha   (Czech Republic)

Author keywords

EGFR gene; EGFR mutation; EGFR protein; Molecular targeted therapy; NSCLC; Protein kinase inhibitors

Indexed keywords

VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; EUROPE; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENETIC SCREENING; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; THERAPY EFFECT; DRUG ANTAGONISM; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84865483075     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-2139.
2. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676): 1497-1500.
3. Gandhi J, Zhang J, Xie Y et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009; 4(2): e4576.
4. Minárik M, Benešová L, Belšá nová B et al. Vliv mutací genů EGFR a KRAS na prognózu přežití u pacientů s nemalobuněčným karcinomem plic, léčený ch inhibitory tyrosin-kináz (srovnání výsledků léčby gefitinibem a erlotinibem). Stud Pneumol Phtiseol 2009; 69(3): 96-104.
5. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23(25): 5900-5909.
6. Bonanno L, Schiavon M, Nardo G et al. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res 2010; 30(12): 5121-5128.
7. Liu HP, Isaac Wu HD, Chang JW et al. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol 2010; 5(8): 1175-1184.
8. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26(26): 4268-4275.
9. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24(31): 5034-5042.
10. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28(5): 744-752.
11. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer. a multicentre, randomised, placebo-controlled phase3study Lancet Oncol 2010; 11(6): 521-529.
12. Brugger W, Triller N, Blasinska-Morawiec M et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J Clin Oncol 2009; 27 (Suppl): 15. Abstract 8020.
13. Pesek M, Benesova L, Belsanova B et al. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res 2009; 29(7): 2767-2773.
14. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer. role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28 (Suppl 1): S24-S31.
15. Zhang Z, Stiegler AL, Boggon TJ et al. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 2010; 1(7): 497-514.
16. Sequist LV, Bell DW, Lynch TJ et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25(5): 587-595.
17. Gandara DR, Lara PN Jr, Mack P et al. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer 2009; 10(3): 148-150.
18. West H, Lilenbaum R, Harpole D et al. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol 2009; 4 (9 Suppl 2): S1029-S1039.
19. Forbes SA, Bhamra G, Bamford S et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008; Chapter 10: Unit 10.11.
20. Shukuya T, Takahashi T, Kaira R et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 2011; 102(5): 1032-1037.
21. Yamamoto H, Shigematsu H, Nomura M et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008; 68(17): 6913-6921.
22. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11(8): 753-762.
23. Kawano O, Sasaki H, Endo K et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006; 54(2): 209-215.
24. Lee SY, Kim MJ, Jin G et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010; 5(11): 1734-1740.